Fasudil Hydrochloride

Fasudil, the first Rho kinase inhibitor approved for clinical use, selectively inhibits the final stage of vascular smooth muscle contraction at two key targets. It also specifically suppresses the movement of inflammatory cytoskeletal proteins, making it an effective tool for both preventing and treating vasospasm. Renowned as a valuable adjunct in managing cerebral vasospasm, Fasudil offers targeted therapy with excellent safety profiles, ensuring that systemic blood pressure remains unaffected.